InvestSMART

Dimerix Limited (ASX: DXB) - Financials

Current share price for DXB : $0.260 0.02 (8.33%)+

Dimerix Limited (DXB) is a clinical-stage biopharmaceutical company focused on improving the lives of patients with inflammatory diseases, including kidney disease. The company is developing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for orphan respiratory / renal Disease. Both DMX-200 and DMX-700 were identified using Dimerix's proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), a scalable and globally applicable technology platform that enables the understanding of receptor interactions to rapidly screen and identify new drug opportunities.

DXB Per Share

Year to Jun Sales Cashflow Earnings Dividends Franking Book Value Average
Annual P/E		 Relative P/E Shareholder Return
2025 $0.01 7 ¢ -2.4 ¢ 0 ¢ 0% $0.02 0 0% 12.7%
2024 -1.6 ¢ -3.8 ¢ 0 ¢ 0% $0.03 0 0% 724.5%
2023 -3.9 ¢ -4.2 ¢ 0 ¢ 0% $0.02 0 0% -47.6%

DXB Capital Structure

Total Debt Interest Long Term Debt Percent Debt Preferred Stock Share Equity Percent Equity
$97.50 $0.00 $0.00 0% $0.00 $13,379 100%
Note: All dollars in thousands ('000) for the table above

DXB Historical Financials

2025 2024 2023
Revenue ($M) 5.6 0.4
Operating Margin (%) -570.7 -4,221.8
Depreciation ($M) -0.1 -0.1
Amortisation ($M)
Net Profit Before Abs ($M) -13.3 -17.1 -13.8
Net Profit After Abs ($M) -13.3 -17.1 -13.8
Income Tax Rate (%) 58.2
Net Profit Margin (%) -237.2 -4,190.6
Employees ($T)
Long Term Debt ($M) 0.1
Shareholders Equity ($M) 13.4 18.2 6
Return on Capital (%) -99 -94 -231
Return on Equity (%) -99.1 -93.9 -231.5
Payout Ratio (%)

DXB Cashflow

2025 2024 2023
Customer Receipts ($M) 55 11
Net Operating Cashflow ($M) 39.05 -7 -12.73
Net Investing Cashflow ($M)
Net Financing Cashflow ($M) 7 21 11

DXB Market & Earnings

2025 2024 2023
Market Cap ($M) 344 281 24
Net Gearing (%) -509.6 -120.9 -34.1
Net Interest Cover (%) 97.9 98 376.2
Dividend Yield (%)
NTA Per Share ($) 0.02 0.03 0.02
EBITDA ($M) -31.9 -17.2 -13.8
EBIT ($M) -32 -17.3 -13.8
EBT Before Abs ($M) -31.7 -17.1 -13.8

DXB Balance Sheet

2025 2024 2023
Cash ($M) 68.28 22.14 7.99
Debtors ($M) 0.52
Other Debtors ($M) 3.64 8.99 9.55
Prepayments ($M) 0.25 0.26 0.18
Inventories ($M)
Current Investments ($M)
Other Current Assets ($M) 0.02
Total Current Assets ($M) 72.2 31.9 17.8
Receivables ($M)
Inventories ($M)
Property, Plant & Equipment ($M) 0.41 0.22 0.04
Accumulated Depreciation ($M) -0.29 -0.06 -0.03
Intangibles ex. Goodwill ($M)
Goodwill ($M)
Future Income Tax Benefit ($M) 18.9
Non-Current Investments ($M)
Other Non-Current Assets ($M)
Total Non-Current Assets ($M) 19 0.16 0.01
Total Assets ($M) 91.2 32.1 17.8
Accounts Payable ($M) 17.5 2.53 5.67
Provisions ($M) 0.33 0.18 0.13
Short Term Debt ($M) 0.1 0.08 5.96
Other Current Liabilities ($M) 4.23 0.57
Total Current Liabilities ($M) 22.16 3.36 11.76
Creditors ($M)
Long Term Debt ($M) 0.07
Provisions ($M) 0.06 0.04 0.04
Other Non-Current Liabilities ($M) 55.58 10.42
Total Non-Current Liabilities ($M) 55.64 10.53 0.04
Total Liabilities ($M) 77.8 13.9 11.8
Share Capital ($M) 90.9 83.4 55.5
Reserves ex. Share Premium ($M) 4.88 3.98 2.57
Share Premium Reserve ($M)
Retained Profits ($M) -82.4 -69.2 -52.1
Other Shareholders Equity ($M)
Convertible Equity ($M)
Outside Equity Interest ($M)
Total Shareholders Equity ($M) 13.38 18.19 5.96

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.